# AZD2171 to Treat Prostate Cancer

> **NCT00436956** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 59 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **PROCEDURE:** Magnetic Resonance Imaging (DCE-MRI)
- **DRUG:** AZD2171
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT00436956
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10-16
- **Primary completion:** 2010-02-01
- **Final completion:** 2014-02-05
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2018-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00436956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00436956, "AZD2171 to Treat Prostate Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00436956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*